ArticleCurrent stem cell reports2018
Induced Pluripotent Stem Cell-Derived Red Blood Cells, Megakaryocytes, and Platelets: Progress and Challenges.
Article in Current stem cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- In vitro erythropoiesis: the emerging potential of induced pluripotent stem cells (iPSCs).Blood science (Baltimore, Md.) · 2025Review
- Tropomyosin 1 deficiency facilitates cell state transitions and enhances hemogenic endothelial cell specification during hematopoiesis.Stem cell reports · 2024Article
- Modeling primitive and definitive erythropoiesis with induced pluripotent stem cells.Blood advances · 2024Article
- Tropomyosin 1 deficiency facilitates cell state transitions to enhance hemogenic endothelial cell specification during hematopoiesis.bioRxiv : the preprint server for biology · 2023Article
- Current status of red blood cell manufacturing in 3D culture and bioreactors.Blood research · 2023Review
- From development toward therapeutics, a collaborative effort on blood progenitors.Stem cell reports · 2021Article
- Tropomyosin 1 genetically constrains in vitro hematopoiesis.BMC biology · 2020Article
- Mechanistic and Translational Advances Using iPSC-Derived Blood Cells.Journal of Experimental Pathology · 2020Article
- Enabling Large-Scale Ex Vivo Production of Megakaryocytes from CD34Stem cells translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Purpose of Review: Human induced pluripotent stem cells (iPSCs) represent an attractive source to generate in vitro-derived red blood cells, megakaryocytes, and platelets for transfusion support. We review the progress made and challenges remaining for generating terminally differentiated red cells and platelets suitable for clinical application. Recent Findings: Human iPSC hematopoietic differentiation protocols primarily recapitulate the primitive stage of hematopoiesis, but a different hematopoietic progenitor that mimics the second wave of hematopoiesis has been identified that generates definitive blood cells. Coupled with strategies to improve maturation and expansion, this provides new opportunities to generate red cells and platelets that can mature, enucleate, and proliferate to clinical scale. Summary: The major challenges of human iPSC-derived transfusion products are terminal differentiation and scalability. Despite these challenges, iPSCs offer a new source for unlimited generation of red cells and platelets with rare phenotypes for transfusion, blood bank reagents, and novel drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.